Vertex Pharmaceuticals Incorporated

NASDAQ:VRTX

Biotechnology

Healthcare
$536.45 -1.40%

-$6.43 today

Market cap
$136.01B
Beta
0.31
P/E (TTM)
26.5
EPS (TTM)
$17.07
52W Low $362.50High $507.92

Volume 1.29M

Average 1.26M

VRTX Weighted Avg Shares (Diluted)

Average shares outstanding including dilutive securities, used to calculate diluted EPS.

Vertex Pharmaceuticals IncorporatedNASDAQ: VRTX

Weighted Avg Shares (Diluted) · Q3 FY2026 · quarter ended Sep 2026

Weighted avg shares (diluted) declines year over year

Q3 FY2026 weighted avg shares (diluted) of 255.2M shares fell 0.9% year over year, in line with the -1.3% change in trailing-twelve-month weighted avg shares (diluted). Sequentially, it fell 0.2% from the prior quarter. Over 3 fiscal years it compounded at -0.1% a year.

Context

  • Weighted avg shares (diluted) increased in 2 of the last 3 fiscal years.

What to watch

Whether quarterly growth of -0.9% holds above the trailing-twelve-month pace of -1.3%.

Sources:Income StatementText generated from reported figures; not investment advice.

Latest quarterSep 2026
255.2M-0.2% QoQ
Last fiscal yearDec 2025
258M+0.0% YoY
LTMSep 2026
255.83M-1.3% YoY
Weighted Avg Shares (Diluted) past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter-0.9%——
1 year+0.0%——
3-year CAGR-0.1%——
5-year CAGR——
10-year CAGR——

Weighted Avg Shares (Diluted) history

Shares · from the income statement

Latest · FY2025
258M USD
Year-over-year change
+0.0%
4-year CAGR
-0.2%

Weighted Avg Shares (Diluted) vs competitors

How VRTX compares with its peers on the latest reported figures

  • VRTX's LTM Sep 2026 weighted avg shares (diluted) of 255.83M shares is the highest of the 11 companies compared; the peer median is 109.29M shares.
  • Its year-over-year change of -1.3% is the lowest of 11, against a peer median of +6.8%.
  • Over three fiscal years its annual growth of -0.1% compares with a peer median of +6.7%.
VRTX Competitors Peer median
Weighted Avg Shares (Diluted) for VRTX and competitors
Company Period LTM YoY 3-year CAGR
VRTXVertex Pharmaceuticals IncorporatedLTM Sep 2026255.83M -1.3%-0.1%
BMRNBioMarin Pharmaceutical Inc.LTM Sep 2026195.7M +0.1%+1.5%
BBIOBridgeBio Pharma, Inc.LTM Jun 2026194.58M +2.6%+10.2%
IONSIonis Pharmaceuticals, Inc.LTM Sep 2026164.62M -0.2%+4.1%
ALNYAlnylam Pharmaceuticals, Inc.LTM Jun 2026137.53M +6.5%+3.4%
NTLAIntellia Therapeutics, Inc.LTM Mar 2026110.2M +9.3%+12.1%
SRPTSarepta Therapeutics, Inc.LTM Mar 2026108.39M +6.9%+6.2%
BEAMBeam Therapeutics Inc.LTM Jun 2026103.77M +17.0%+12.2%
RAREUltragenyx Pharmaceutical Inc.LTM Mar 202699.68M +6.6%+12.1%
CRSPCRISPR Therapeutics AGLTM Sep 202694.81M +8.4%+5.0%
PTCTPTC Therapeutics, Inc.LTM Jun 202685.59M +7.4%+7.2%
Peer median (excluding VRTX) 109.29M+6.8%+6.7%

Competitors are the stored peer set for VRTX. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Income Statement

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Revenue7.57B8.93B9.87B11.02B12.07B
Cost of Revenue904.2M1.08B1.26B1.53B1.81B
Gross Profit6.67B7.85B8.61B9.49B10.27B
Gross Margin88.1%87.9%87.2%86.1%85.0%
Research & Development3.05B2.66B3.16B3.63B3.75B
Selling, General & Admin840.1M944.7M1.14B1.46B1.75B
Operating Expenses3.89B3.54B4.78B9.72B5.51B
Depreciation & Amortization125.6M148.3M181.3M207.2M209.8M
EBITDA2.92B4.44B4.61B486.3M4.87B
EBITDA Margin38.5%49.7%46.7%4.4%40.3%
Operating Income2.78B4.31B3.83B(232.9M)4.76B
Operating Margin36.7%48.2%38.8%-2.1%39.4%
Interest Income4.9M144.6M614.7M598.1M490.9M
Interest Expense61.5M54.8M44.1M30.6M13.3M
Other Income / Expenses(51.7M)(75M)547.8M481.4M(117.5M)
Income Before Tax2.73B4.23B4.38B248.5M4.64B
Pre-Tax Margin36.0%47.4%44.4%2.3%38.5%
Income Tax Expense388.3M910.4M760.2M784.1M690M
Net Income2.34B3.32B3.62B(535.6M)3.95B
Net Margin30.9%37.2%36.7%-4.9%32.7%
EPS (Basic)9.0912.9714.05(2.08)15.46
EPS (Diluted)9.0112.8213.89(2.08)15.32
Weighted Avg Shares257.7M256.1M257.7M257.5M255.7M
Weighted Avg Shares (Diluted)259.9M259.1M260.5M257.9M258M

Vertex Pharmaceuticals Incorporated

NASDAQ:VRTX

Intrinsic Alpha fair value

Locked

Current Price

$536.45

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.